全文获取类型
收费全文 | 7983篇 |
免费 | 518篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 400篇 |
妇产科学 | 243篇 |
基础医学 | 700篇 |
口腔科学 | 13篇 |
临床医学 | 786篇 |
内科学 | 3627篇 |
皮肤病学 | 98篇 |
神经病学 | 753篇 |
特种医学 | 72篇 |
外科学 | 640篇 |
综合类 | 270篇 |
一般理论 | 1篇 |
预防医学 | 371篇 |
眼科学 | 60篇 |
药学 | 187篇 |
中国医学 | 1篇 |
肿瘤学 | 291篇 |
出版年
2024年 | 4篇 |
2023年 | 97篇 |
2022年 | 54篇 |
2021年 | 124篇 |
2020年 | 69篇 |
2019年 | 37篇 |
2018年 | 157篇 |
2017年 | 142篇 |
2016年 | 188篇 |
2015年 | 182篇 |
2014年 | 173篇 |
2013年 | 213篇 |
2012年 | 880篇 |
2011年 | 935篇 |
2010年 | 282篇 |
2009年 | 241篇 |
2008年 | 818篇 |
2007年 | 748篇 |
2006年 | 705篇 |
2005年 | 668篇 |
2004年 | 517篇 |
2003年 | 521篇 |
2002年 | 352篇 |
2001年 | 260篇 |
2000年 | 41篇 |
1999年 | 17篇 |
1998年 | 35篇 |
1997年 | 13篇 |
1996年 | 16篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有8514条查询结果,搜索用时 15 毫秒
171.
172.
Styles L Wager CG Labotka RJ Smith-Whitley K Thompson AA Lane PA McMahon LE Miller R Roseff SD Iyer RV Hsu LL Castro OL Ataga KI Onyekwere O Okam M Bellevue R Miller ST;Sickle Cell Disease Clinical Research Network 《British journal of haematology》2012,157(5):627-636
Acute chest syndrome (ACS) is defined as fever, respiratory symptoms and a new pulmonary infiltrate in an individual with sickle cell disease (SCD). Nearly half of ACS episodes occur in SCD patients already hospitalized, potentially permitting pre-emptive therapy in high-risk patients. Simple transfusion of red blood cells may abort ACS if given to patients hospitalized for pain who develop fever and elevated levels of secretory phospholipase A2 (sPLA2). In a feasibility study (PROACTIVE; ClinicalTrials.gov NCT00951808), patients hospitalized for pain who developed fever and elevated sPLA2 were eligible for randomization to transfusion or observation; all others were enrolled in an observational arm. Of 237 enrolled, only 10 were randomized; one of the four to receive transfusion had delayed treatment. Of 233 subjects receiving standard care, 22 developed ACS. A threshold level of sPLA2 ≥ 48 ng/ml gave optimal sensitivity (73%), specificity (71%) and accuracy (71%), but a positive predictive value of only 24%. The predictive value of sPLA2 was improved in adults and patients with chest or back pain, lower haemoglobin concentration and higher white blood cell counts, and in those receiving less than two-thirds maintenance fluids. The hurdles identified in PROACTIVE should facilitate design of a larger, definitive, phase 3 randomized controlled trial. 相似文献
173.
Czuczman MS Hess G Gadeberg OV Pedersen LM Goldstein N Gupta I Jewell RC Lin TS Lisby S Strange C Windfeld K Viardot A; Study Investigators 《British journal of haematology》2012,157(4):438-445
An international, Phase II trial was conducted to assess two doses of ofatumumab, a human CD20 monoclonal antibody, combined with cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), prednisone (100 mg days 3–7) and vincristine (1·4 mg/m2) (O‐CHOP), as frontline treatment for follicular lymphoma (FL). 59 patients with previously untreated FL were randomized to ofatumumab 500 mg (n = 29) or 1000 mg (n = 30) day 1, with CHOP on day 3 every 3 weeks for six cycles. Median duration of FL was 0·1 years for both dose groups; 34% and 38% of patients had high‐risk Follicular Lymphoma International Prognostic Index (FLIPI) scores in the 500‐ and 1000‐mg dose groups, respectively. Overall response rate was 90% for the 500‐mg group and 100% for the 1000‐mg group. 62% of patients achieved complete response (CR)/unconfirmed CR (CRu). 76% of patients with FLIPI score 3–5 attained CR/CRu. Longer follow‐up time is needed for analysis of survival end points. The most common Common Terminology Criteria grade 3–4 investigator‐reported adverse events were leucopenia (29%) and neutropenia (22%). No deaths have been reported. O‐CHOP was safe and efficacious in patients with previously untreated FL, including high‐risk FLIPI groups. This trial was registered at www.clinicaltrials.gov (NCT00494780). 相似文献
174.
175.
Chirinos JA Segers P Gillebert TC Gupta AK De Buyzere ML De Bacquer D St John-Sutton M Rietzschel ER;Asklepios Investigators 《Hypertension》2012,60(1):64-70
Myocardial and arterial load are time-varying phenomena. Despite their importance in myocardial function, the arterial properties that determine time-resolved myocardial wall stress are unknown. We aimed to assess arterial properties as determinants of time-resolved myocardial stress among 1214 men and women enrolled in the Asklepios Study. Time-resolved central pressure, flow, and left ventricular geometry were measured with carotid tonometry, Doppler, and speckle-tracking echocardiography, respectively, for computation of arterial load and ejection-phase time-varying myocardial wall stress. For any given end-diastolic left ventricular geometry and cardiac output, peak myocardial stress correlated directly with systemic vascular resistance (standardized β=1.12; P<0.0001) and aortic characteristic impedance (standardized β=0.17; P<0.0001). The ejection-phase stress-time integral correlated with systemic vascular resistance (standardized β=1.06; P<0.0001), lower total arterial compliance (standardized β=-0.13; P=0.0008), and earlier return of wave reflections (standardized β=-0.10; P<0.0001) but not with reflection magnitude, whereas end-systolic wall stress correlated with systemic vascular resistance (standardized β=1.06; P<0.0001) and reflection magnitude (standardized β=0.12; P<0.0001). After adjustment for age, all of the measured arterial properties, end-diastolic left ventricular geometry, and cardiac output, women demonstrated greater peak (534 versus 507 kdyne/cm(2); P<0.0001), end-systolic (335 versus 320 kdyne/cm(2); P<0.0001), and ejection-phase stress-time integral (157 versus 142 kdyne · s · cm(-2); P<0.0001). In conclusion, different arterial properties have selective effects on time-resolved ejection-phase myocardial wall stress, which are not apparent from single-time point measurements. Women demonstrate less efficient myocardial-arterial coupling, with higher wall stress development for any given left ventricular geometry, arterial properties, and flow output. These observations may relate to the differential susceptibility of women to heart failure. 相似文献
176.
J Ishikawa S Hoshide K Eguchi S Ishikawa K Shimada K Kario;for the Japan Morning Surge-Home Blood Pressure Study Investigators Group 《Hypertension》2012,60(4):921-928
In ambulatory blood pressure (BP) monitoring, nighttime BP has a superior ability to predict hypertensive target organ damage than awake BP. We evaluated whether nighttime BP, assessed by a home BP monitor, was associated with hypertensive target organ damage. We measured clinic BP, out-of-clinic BP including nighttime home BP, and the urinary albumin:creatinine ratio (UACR) in 854 patients who had cardiovascular risk factors. Nighttime home BP was measured at 2:00, 3:00, and 4:00 am, in addition to clinic, awake ambulatory, nighttime ambulatory, and awake home BP. Nighttime home systolic BP (SBP) was slightly higher than nighttime ambulatory SBP (difference, 2.6 mm Hg; P<0.001). Clinic (r=0.186), awake ambulatory (r=0.173), nighttime ambulatory (r=0.194), awake home (r=0.298), and nighttime home (r=0.311) SBPs were all associated with log-transformed UACR (all P<0.001). The correlation coefficient for the relationship between nighttime home SBP and log-transformed UACR was significantly greater than that for the relationship between nighttime ambulatory SBP and log-transformed UACR (P<0.001). The goodness of fit of the association between SBP and UACR was improved by adding nighttime home SBP to the other SBPs (P<0.001). Nighttime home diastolic BP also improved the goodness-of-fit of the association between diastolic BP and UACR (P=0.001). Similar findings were observed for the left ventricular mass index in the subgroup (N=594). In conclusion, nighttime home BP is slightly different from (but comparable to) nighttime ambulatory BP. The addition of nighttime home BP to other BP measures improves the association of BP with hypertensive target organ damage. 相似文献
177.
178.
179.
Fukumoto S Ishimura E Motoyama K Morioka T Kimoto E Wakikawa K Shoji S Koyama H Shoji T Emoto M Nishizawa Y Inaba M;Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients 《Diabetes research and clinical practice》2012,97(1):91-98
We evaluated the antialbuminuric advantage of cilnidipine, an N/L-type calcium channel blocker (CCB), compared with L-type CCBs in diabetic patients with normoalbuminuria and microalbuminuria. The study was a multicenter, non-randomized crossover trial. Participants were 90 type 2 diabetic patients exhibiting either normo- or microalbuminuria, and undergoing CCB treatment for ≥6 months prior to study entry. The CCB at the time of entry was continued for the first 6 months (Period 1). Treatment was subsequently switched from cilnidipine to an L-type CCB, or vice versa, for the second 6-month observation period (Period 2). During Period 1, the L-type CCB group showed a significant increase of urinary albumin excretion (UAE) over time, while the cilnidipine group showed no significant elevation. During Period 2, switching of the treatment from the L-type CCB to cilnidipine resulted in significant reduction of the UAE, whereas switching from cilnidipine to the L-type CCB resulted in no significant change in the UAE. This study demonstrated that the antialbuminuric effect of Cilnidipine, but not the L-type CCBs, was sustained even in patients treated for a long time. In addition, the antialbuminuric effect can be anticipated after switching from an L-type CCB to cilnidipine, but not vice versa. 相似文献